Deep Lens (acquired by Paradigm) Alternatives & Competitors

12 companies similar to Deep Lens (acquired by Paradigm) — Accelerating clinical trial matching in oncology

Ancora.ai

Ancora.ai is a patient-first, digital clinical trial navigation tool connecting cancer pat...

9 Grant $465.00K

Zurich, Switzerland

AI Big Data +3

Massive Bio

AI-driven system connecting cancer patients to clinical trials in real time. Industrializi...

102 Series B $28.10M

Istanbul, Turkey

AI Big Data +5

XGC Software Inc

AI + ERP + Blockchain: Enabling Next-Generation Caregiving, Healthcare Technology, and Cli...

4 Series A

Toronto, Canada

AI Blockchain +2

HealthMatch

Connecting People To Revolutionary Drugs And Potential Cures

24 Series C $35.30M

Australia

Biotechnology Health Care +2

Track all Deep Lens (acquired by Paradigm) competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

Virgo

Accelerate clinical trials with AI for endoscopy.

33 Venture round $9.61M

San Francisco, United Sta...

AI Computer Vision +4

Singularity.AI

Unlocking Visual Collaboration for Medical Innovation

4 Convertible Note $5.00M

Mountain View, United Sta...

AI Health Care +3

Aiforia Technologies

Translate images into data, discoveries, and diagnoses with deep learning AI for image ana...

79 IPO $65.00M

Helsinki, Finland

AI Biotechnology +5

Bayesian Health

Co-pilot for doctors and nurses — empowering clinicians with real-time care signals to man...

32 Venture round $15.23M

New York, United States

AI Health Care +1

Deep Bio Inc.

Al healthcare company with in-house expertise in deep learning and cancer pathology.

30 Series B $5.60M

Seoul, Korea South

AI Biotechnology +1

radiomics.bio

Radiomics, Deep Learning & Federated Learning for AI powered drug development trajectory a...

Liege, Belgium

AI Biotechnology +1

Sano Genetics

Accelerating the world's transition to precision medicine.

50 $20.86M

Cambridge, United Kingdom

Biopharma Biotechnology +2

QMENTA

Medical imaging software solutions that improve outcomes for research, and clinical trials

45 Debt Financing $9.69M

Boston, United States

AI Analytics +3

About Deep Lens (acquired by Paradigm)

Deep Lens, with the slogan "Accelerating clinical trial matching in oncology," is a digital healthcare company that was established in 2017 and is headquartered in the United States. The company focuses on leveraging AI, machine learning, and life sciences to expedite the recruitment of suitable cancer patients for cli...

Taxonomy

Digital Healthcare, Clinical Trials, Oncology, AI-driven Platform, Cancer Patient Recruitment, Digital Pathology Workflow, AI Image Detection, Collaboration Platform, Cloud Storage, API Integration, Pathology Research, Pharmaceuticals, Cancer Research, Pathology

Frequently Asked Questions

Companies similar to Deep Lens (acquired by Paradigm) include Ancora.ai, Massive Bio, XGC Software Inc, HealthMatch , Virgo. They work in AI and Health Care and share Deep Lens (acquired by Paradigm)'s focus on oncology, clinical trials and pharmaceuticals.

Bounce Watch lists 12 companies that share Deep Lens (acquired by Paradigm)'s industries and are closest to it in business tags, services, target customers, business model and size.

Don't just read about them. Follow them.

BounceWatch watches Deep Lens (acquired by Paradigm) and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

Deep Lens (acquired by Paradigm) Profile Ancora.ai Alternatives Massive Bio Alternatives XGC Software Inc Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at Deep Lens (acquired by Paradigm) on 11 Sep 2024. The 12 companies listed here were last checked between 11 Sep 2024 and 2 Sep 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.